Nagata Y, Goto T, Teramoto Y, Matsukawa T, Fujimoto N, Miyamoto H
Am J Cancer Res. 2024; 14(2):696-708.
PMID: 38455412
PMC: 10915320.
Zhang Y, Huang Z, Li K, Xie G, Feng Y, Wang Z
J Exp Clin Cancer Res. 2024; 43(1):16.
PMID: 38200609
PMC: 10782585.
DOI: 10.1186/s13046-023-02920-w.
Tatenuma T, Miyamoto H
Drug Des Devel Ther. 2023; 17:2325-2333.
PMID: 37559910
PMC: 10408655.
DOI: 10.2147/DDDT.S373546.
Chen J, Yuan Y, Fang M, Zhu Y, Sun X, Lou Y
Front Endocrinol (Lausanne). 2023; 13:1074540.
PMID: 36733800
PMC: 9887024.
DOI: 10.3389/fendo.2022.1074540.
Angulo J, Ciria Santos J, Gomez-Caamano A, Poza de Celis R, Gonzalez Sala J, Garcia Garzon J
World J Urol. 2022; 40(10):2459-2466.
PMID: 36057895
PMC: 9512882.
DOI: 10.1007/s00345-022-04108-x.
Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments.
Goldberg I, Lichtbroun B, Singer E, Ghodoussipour S
Arch Pharmacol Ther. 2022; 4(1):13-22.
PMID: 36051251
PMC: 9431226.
Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.
Sager R, Backe S, Ahanin E, Smith G, Nsouli I, Woodford M
Nat Rev Urol. 2022; 19(5):305-320.
PMID: 35264774
PMC: 9306014.
DOI: 10.1038/s41585-022-00571-8.
Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.
Gu Y, Xue M, Wang Q, Hong X, Wang X, Zhou F
Int J Mol Sci. 2021; 22(24).
PMID: 34948018
PMC: 8704202.
DOI: 10.3390/ijms222413222.
Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies.
Singla R, Sharma P, Dubey A, Gundamaraju R, Kumar D, Kumar S
Front Pharmacol. 2021; 12:732266.
PMID: 34737700
PMC: 8560712.
DOI: 10.3389/fphar.2021.732266.
Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges.
Sun G, Rong D, Li Z, Sun G, Wu F, Li X
Front Cell Dev Biol. 2021; 9:694363.
PMID: 34568317
PMC: 8455877.
DOI: 10.3389/fcell.2021.694363.
Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer.
Fontana F, Limonta P
Cells. 2021; 10(5).
PMID: 34067217
PMC: 8151003.
DOI: 10.3390/cells10051133.
Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells.
Zhai B, Li Y, Kotapalli S, Bacha J, Brown D, Steino A
Cell Death Dis. 2020; 11(7):577.
PMID: 32709853
PMC: 7381652.
DOI: 10.1038/s41419-020-02780-8.
Pyrimethamine Elicits Antitumor Effects on Prostate Cancer by Inhibiting the p38-NF-κB Pathway.
Zhou X, Zhang J, Hu X, He P, Guo J, Li J
Front Pharmacol. 2020; 11:758.
PMID: 32523533
PMC: 7261869.
DOI: 10.3389/fphar.2020.00758.
γ-Tocotrienol and α-Tocopherol Ether Acetate Enhance Docetaxel Activity in Drug-Resistant Prostate Cancer Cells.
Asay S, Graham A, Hollingsworth S, Barnes B, Oblad R, Michaelis D
Molecules. 2020; 25(2).
PMID: 31963634
PMC: 7024271.
DOI: 10.3390/molecules25020398.
Effect of aberrantly methylated androgen receptor target gene PCDH7 on the development of androgen-independent prostate cancer cells.
Xu S, Wu X, Tao Z, Li H, Fan C, Chen S
Genes Genomics. 2019; 42(3):299-307.
PMID: 31872382
DOI: 10.1007/s13258-019-00903-w.
Role of the androgen signaling axis in genitourinary malignancies.
Shinder B, Shupe A, Lee G, Stein M, Kim I, Singer E
Transl Cancer Res. 2019; 7(4):1135-1142.
PMID: 30701159
PMC: 6349041.
DOI: 10.21037/tcr.2018.03.41.
Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells.
Johnson B, Radwan F, Hossain A, Doonan B, Hathaway-Schrader J, God J
J Cell Biochem. 2018; 120(4):6264-6276.
PMID: 30378157
PMC: 6561659.
DOI: 10.1002/jcb.27913.
Estradiol-ERβ2 signaling axis confers growth and migration of CRPC cells through TMPRSS2-ETV5 gene fusion.
Kim H, Datta A, Talwar S, Saleem S, Mondal D, Abdel-Mageed A
Oncotarget. 2017; 8(38):62820-62833.
PMID: 28968951
PMC: 5609883.
DOI: 10.18632/oncotarget.11355.
Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer.
Wu J, Chen W, Zhang W, Zhang J, Liu J, Jiang Y
Oncotarget. 2017; 8(35):59709-59719.
PMID: 28938674
PMC: 5601770.
DOI: 10.18632/oncotarget.19810.
Lack of an association between the aPKCλ/ι expression in prostate cancer and the patient outcomes.
Yokomizo Y, Kawahara T, Nagashima Y, Ishiguro H, Kato I, Yao M
Int J Surg Case Rep. 2017; 37:180-182.
PMID: 28697433
PMC: 5504077.
DOI: 10.1016/j.ijscr.2017.06.047.